Search Prime Grants

U01HG011176

Cooperative Agreement

Overview

Grant Description
Genomic risk in clinic care to promote health equity in New York City patients.
Awardee
Icahn School Of Medicine At Mount Sinai
Funding Goals
NHGRI SUPPORTS THE DEVELOPMENT OF RESOURCES AND TECHNOLOGIES THAT WILL ACCELERATE GENOME RESEARCH AND ITS APPLICATION TO HUMAN HEALTH AND GENOMIC MEDICINE. A CRITICAL PART OF THE NHGRI MISSION CONTINUES TO BE THE STUDY OF THE ETHICAL, LEGAL AND SOCIAL IMPLICATIONS (ELSI) OF GENOME RESEARCH. NHGRI ALSO SUPPORTS THE TRAINING AND CAREER DEVELOPMENT OF INVESTIGATORS AND THE DISSEMINATION OF GENOME INFORMATION TO THE PUBLIC AND TO HEALTH PROFESSIONALS. THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM IS USED TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM IS USED TO FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
93.172 - Human Genome Research
Awarding / Funding Agency
National Human Genome Research Institute (NHGRI) [HHS - NIH]
Place of Performance
New York, New York 100296504 United States
Geographic Scope
Single Zip Code
Related Opportunity
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) (PA-20-272)
Analysis Notes
Amendment Since initial award the End Date has been extended from 04/30/25 to 04/30/26 and the total obligations have increased 570% from $1,401,278 to $9,385,998.
Icahn School Of Medicine At Mount Sinai was awarded Genomic risk in clinic care to promote health equity in New York City patients Cooperative Agreement U01HG011176 worth $9,385,998 from National Human Genome Research Institute in July 2020 with work to be completed primarily in New York New York United States. The grant has a duration of 5 years 9 months and was awarded through assistance program 93.172 Human Genome Research. The Cooperative Agreement was awarded through grant opportunity Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Status
(Ongoing)

Last Modified 8/20/25

Period of Performance
7/1/20
Start Date
4/30/26
End Date
88.0% Complete

Funding Split
$9.4M
Federal Obligation
$0.0
Non-Federal Obligation
$9.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01HG011176

Transaction History

Modifications to U01HG011176

Additional Detail

Award ID FAIN
U01HG011176
SAI Number
U01HG011176-4290159443
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N400 NIH National Human Genome Research Institute
Funding Office
75N400 NIH National Human Genome Research Institute
Awardee UEI
C8H9CNG1VBD9
Awardee CAGE
1QSQ9
Performance District
NY-13
Senators
Kirsten Gillibrand
Charles Schumer

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Human Genome Research Institute, National Institutes of Health, Health and Human Services (075-0891) Health research and training Grants, subsidies, and contributions (41.0) $5,392,990 100%
Modified: 8/20/25